Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by Sigma Planning Corp

Sigma Planning Corp reduced its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,069 shares of the biopharmaceutical company’s stock after selling 232 shares during the quarter. Sigma Planning Corp’s holdings in Horizon Therapeutics Public were worth $404,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Atria Investments LLC boosted its stake in Horizon Therapeutics Public by 5.2% during the 1st quarter. Atria Investments LLC now owns 10,312 shares of the biopharmaceutical company’s stock valued at $1,085,000 after purchasing an additional 507 shares in the last quarter. Arizona State Retirement System boosted its stake in Horizon Therapeutics Public by 2.7% during the 1st quarter. Arizona State Retirement System now owns 59,981 shares of the biopharmaceutical company’s stock valued at $6,311,000 after purchasing an additional 1,554 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Horizon Therapeutics Public by 0.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 271,865 shares of the biopharmaceutical company’s stock valued at $28,603,000 after purchasing an additional 1,229 shares in the last quarter. Banque Pictet & Cie SA boosted its stake in Horizon Therapeutics Public by 4.0% during the 1st quarter. Banque Pictet & Cie SA now owns 25,274 shares of the biopharmaceutical company’s stock valued at $2,659,000 after purchasing an additional 978 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in Horizon Therapeutics Public by 18.4% during the 1st quarter. New York State Common Retirement Fund now owns 317,093 shares of the biopharmaceutical company’s stock valued at $33,361,000 after purchasing an additional 49,224 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on HZNP. HC Wainwright began coverage on Horizon Therapeutics Public in a research note on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price target for the company. Morgan Stanley reduced their price objective on Horizon Therapeutics Public from $135.00 to $90.00 and set an “overweight” rating for the company in a research note on Thursday, August 4th. TheStreet raised Horizon Therapeutics Public from a “c+” rating to a “b-” rating in a research note on Tuesday. UBS Group lowered Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $137.00 to $71.00 in a research note on Thursday, August 4th. Finally, BMO Capital Markets reduced their price objective on Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating for the company in a research note on Thursday, August 4th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.00.

Horizon Therapeutics Public Price Performance

HZNP opened at $77.53 on Friday. The stock has a fifty day moving average of $67.79 and a 200-day moving average of $74.34. The firm has a market capitalization of $17.57 billion, a P/E ratio of 31.77, a PEG ratio of 1.54 and a beta of 1.09. Horizon Therapeutics Public Limited has a 12-month low of $57.84 and a 12-month high of $117.49. The company has a quick ratio of 3.74, a current ratio of 3.96 and a debt-to-equity ratio of 0.51.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Featured Articles

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.